Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLI1100 in moderate-severe facial acne vulgaris
NCT01241331Phase 2Completed
- Sponsor
- Braintree Laboratories
- Start
- Nov 2010
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acne vulgaris comparing BLI1100 with Vehicle (2 arms). Primary endpoint: Percent reduction of total acne lesion counts at 12 weeks. Started Nov 2010; status: completed.
02
Drugs
BLI1100
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT01241331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01241331.